Who are Metformin, glyburide and insulin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-glyburide-and-insulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Metformin, glyburide and insulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin, glyburide and insulin (Metformin, glyburide and insulin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiabetic combination therapy (biguanide + sulfonylurea + insulin). Area: Diabetes.

phase 3 Antidiabetic combination therapy (biguanide + sulfonylurea + insulin) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin, glyburide and insulin (Metformin, glyburide and insulin) — Université de Sherbrooke. This combination therapy addresses type 2 diabetes through three complementary mechanisms: metformin reduces hepatic glucose production, glyburide stimulates pancreatic insulin secretion, and insulin provides direct glucose-lowering action.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin, glyburide and insulin TARGET	Metformin, glyburide and insulin	Université de Sherbrooke	phase 3	Antidiabetic combination therapy (biguanide + sulfonylurea + insulin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiabetic combination therapy (biguanide + sulfonylurea + insulin) class)

Université de Sherbrooke · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin, glyburide and insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-glyburide-and-insulin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab